Chronic kidney disease (CKD) is frequently associated with protein energy wasting which has been recognized as a strong predictive factor of mortality. Zinc 2-glycoprotein (ZAG) has been proposed as a new adipokine involved in body weight control through its 
Introduction
Chronic kidney disease (CKD) is characterized by non specific metabolic disturbances as protein-energy wasting (PEW) (1), insulin resistance and dyslipidemia (2,3). Despite improved treatments and nutritional support, all of these are still responsible for high mortality rate, mostly from cardiovascular events (4, 5) . Several causes of CKD-associated dysmetabolism have been identified, including acidosis, inflammation and oxidative stress (6 8) but the pathogenesis remains unclear. White adipose tissue (WAT) is an endocrine organ since it -releases a large number of bioactive compounds called adipokines. Their endocrine or paracrine activities contribute to the regulation of energy balance, inflammatory response and could play a key role in the etiology of uremia-associated insulin resistance and cachexia (9-11). Zinc 2-glycoprotein (thereafter referred to as ZAG) is a 43 kDa glycoprotein isolated from human plasma (12, 13) . ZAG is secreted α in large amount by WAT but also by epithelia cells from liver, breast, gastrointestinal tract as well as sweat glands (14) . ZAG has attracted extensive researches since it acts as a lipid-mobilizing factor. Clinically, ZAG is overexpressed in some malignant tumors and is strongly associated with the loss of adipose tissues in cancer cachexia (15 17). In contrast, expression of ZAG is rather low in obese rodents and
Results

Patient data
Clinical and biological characteristics of healthy volunteers (HV), chronic kidney disease (CKD), haemodialysis (HD) and peritoneal dialysis (PD) patients are summarized in Table 1 . As expected, plasma creatinine and renal function were the only significant differences between the groups. ZAG was quantified by enzyme immunoassay in individual plasmas. ZAG plasma concentration was 2-fold higher in CKD patients as compared with healthy volunteers (Table 1) ( 226 , n 8, p<0.05) . Pre and post-dialysis patients also exhibited further + % = increases in ZAG plasma concentration. The mean plasma ZAG concentration was 125 65 g/ml before and 145 43 g/ml after ± μ ± μ haemodialysis session ( 18 , p<0.05).
+ %
Uremic plasma pool increases ZAG protein content in 3T3-L1 adipocytes 3T3-L1 adipocytes were incubated for 16h with HV, CKD, HD or PD human plasma pools and ZAG content was measured using WB ( Figure 1A ,B). Incubation of 3T3-L1 adipocytes with CKD and HV pools slightly decreased cell viability as measured by MTT and LDH assay (Supplementary Table 1 ). The presence of ZAG in control 3T3-L1 cells was almost undetectable while treatment with CKD pool induced a significant increase in ZAG content as compared with HV pool ( 124 , p<0.001). Incubation with HD pools yielded a similar + % increase of ZAG content ( 143 , p<0.001) in adipocytes while incubation with PD pool had no effect ( Figure 1B ). Since heparinized + % plasma activates lipoprotein lipase which itself could interfere with ZAG production, we compared the effects on 3T3-L1 adipose cells of plasma and serum from the same CKD stage 5 patients. Of note, plasma and sera pools yielded similar increase in ZAG content excluding such effect (Supplementary Figure 1) . Urea at a concentration chosen to mimic uremia (30 mM) did not elicit any increase of ZAG in 3T3-L1 adipocytes. To get further insight into the molecular effect of CKD plasma pool on cellular ZAG content, plasma were heat-inactivated (heat-shock, 65 C for 30 min) or fractionated by ultrafiltration ( Figure 1C ). Heat denaturation did not significantly alter°Z AG production in adipocytes neither for HV nor for CKD pools. Ultrafiltration of the CKD pool with a 10 kDa cut-off dialysis membrane, triggered ZAG overproduction in 3T3-L1 cells while the ultrafiltrate (ie. compounds <10kDa) did not elicit any ZAG overproduction. Taken together these results suggest that the stimulating factor is not a protein (since it resists to heat denaturation) but 
ZAG white adipose tissue content is increased in animal models of CKD
To confirm these results, WAT ZAG content was measured in rodent models of CKD induced by 5/6 nephrectomy in rats and in vitro mice. Nephrectomized rats (Nx5/6) were compared to sham-operated pair-fed rats (SO). The main features of renal function and biometric data of SO and Nx5/6 rats are shown in Supplementary Table 2. Nx5/6 rats exhibited an elevated plasma urea concentration ( 156 , p + % = 0.03), a higher proteinuria ( 650 , p 0.001) and a significant decrease in white adipose tissue accretion (-44 , p 0.006) compared to SO
rats. As shown in Figure 3A , WB analysis of epididymal WAT evidenced a dramatic increase in ZAG content in the Nx5/6 rat WAT as compared to SO rats ( 598 , p<0,02) . That finding demonstrates that renal impairment increases ZAG content in WAT. Using linear + % regression analysis, we found a positive correlation between ZAG tissue content and proteinuria ( Figure 3B , p 0.001) and a negative = correlation with total WAT weight ( Figure 3C , p 0.006) suggesting that ZAG, through its lipolytic and antilipogenic actions, could = contribute to fat mass loss. Fat mass loss was associated in Nx5/6 rats with ectopic lipid redistribution in muscle, as evidenced by the measurement of gastrocnemius total lipid content ( Figure 3D , p 0.002) and liver (data not shown). ZAG is rather low in WAT from obese = rodents and obese human subjects (18, 19) . The effects of nephrectomy on ZAG tissue content was therefore tested in mice fed a high fat diet (HFD) to test the effects of increased fat deposition. Biometric data for these animals are shown in Supplementary function, mice fed a HFD exhibited a striking increase in fat deposition when compared to mice fed a standard diet ( Figure 4A ).
Nephrectomized mice however exhibited a blunted fat accretion when compared to SO mice. ZAG adipose tissue content was strikingly increased in WAT from Nx5/6 mice fed a standard diet as well as in mice fed a HFD ( Figure 4B ) compared to their respective controls. Experimental study in rats and mice indicated that ZAG content was increased by renal impairment; we therefore aimed to assess ZAG content in WAT from CKD patients. Seven stage-5 CKD patients and nine non-CKD patients were recruited from an ongoing study to perform surgical subcutaneous WAT biopsies. To rule out potential selection biases that may contribute to disturb WAT metabolism, evidences of inflammation, cancer diseases, acidosis, diabetes or obesity were considered as exclusion factors. Baseline characteristics of patients are summarized in Table 2 . ZAG plasma concentration was measured by enzyme immunoassay method. As expected, a higher plasma concentration of ZAG was noticed in CKD stage-5 patients compared to non-CKD patients ( 71 , n 7 9, p 0.04). CKD patients
exhibited a higher ZAG content in abdominal subcutaneous WAT than the non-CKD patients ( 573 , n 7 9, p 0.03) ( Table 2 , see
Supplementary Figure 2 for typical blots). Plasma ZAG concentration was further compared in non-CKD and CKD overweighed/obese patients (BMI>30kg.m ) ( Table 3) . A higher plasma concentration of ZAG was noticed in CKD stage-5 obese patients compared to 2 − non-CKD obese patients ( 184 , n 7 8, p<0.005). The ZAG protein white adipose tissue content was analyzed by western blotting in one
obese CKD stage-5 patient compared to one non-CKD obese patient (see Supplementary Figure 3 ). In good agreement with animal studies, ZAG/ Tubulin ratio was strongly increased ( 633 ) in WAT from CKD obese patient compared to non-CKD obese patient + % (ZAG/Tubulin ratio: 0.89 and 6.53 for non-CKD and CKD, respectively).
Discussion
We report in the present study that uremic plasma increases ZAG protein production in 3T3-L1 adipose cells. The clinical relevance of this finding is further confirmed by the observation of increased WAT content of ZAG in CKD animal models as well as in subcutaneous white adipose tissue from CKD Stage 5 patients. These data offer a novel insight into the possible mechanisms of CKD associated metabolic disturbances such as dyslipidemia and protein energy wasting. In good agreement with the study by Philipp et al. in hemodialysis patients (28), the CKD patients included in the present investigation exhibited a marked elevation of plasma ZAG concentration (two-fold, p<0.05) that was also observed in haemodialysis patients. Incubation of 3T3-L1 adipose cells in the medium containing plasma from the CKD patients significantly increased intracellular ZAG protein content compared to that found with plasma from HV. This increase is mainly due to a neo-synthesis of ZAG protein since it is abolished by the use of a protein synthesis inhibitor such as cycloheximide (data not shown). This observation suggests that increased plasma concentration of ZAG reported in CKD could, at least in part, be due to an increased production and secretion as opposed to the decrease of its renal clearance (28,31). To get an insight into the mechanism of uremic plasma induced ZAG production, plasma pool were heat inactivated (30 min, 65 C) or fractionated by°u ltrafiltration (cutoff : 10kDa). Aminzadeh et al (26) reported that uremic plasma induces an exuberant secretion of leptin and that plasma TNF-alpha is involved in this process. However, most cytokines are rapidly inactivated during heat shock (i.e. temperature >50 60 C)
-°e xcluding that the stimulatory factor of ZAG production being a pro-inflammatory cytokine. Supporting this view, overnight incubation of 3T3-L1 adipose cells with two common inflammatory cytokines TNF-alpha and interleukin-6 did not elicit any change in ZAG content (Supplementary Figure 4) . ultrafiltration study indicated that the stimulating factor had a high MW (>10kDa) or was tightly in vitro " " bound to plasma proteins. To test this hypothesis, 3T3-L1 cells were incubated with plasma extensively dialyzed through cellulose membrane (MWCO: 8 kDA) to remove low MW compounds (see Supplementary Figure 5 ). Dialyzed plasma from CKD did not significantly alter ZAG production compared to HV plasma suggesting that stimulating factor could be a small protein-bound uremic
toxin. In good agreement, ultrafiltrate collected from one CKD patient undergoing ultrafiltration to treat fluid overload also failed to trigger ZAG production in 3T3-L1 adipose cells confirming that stimulating factor was either high MW or tightly bound to plasma
proteins (see Supplementary Figure 6 ). Taken together, these data indicate that the stimulating factor (s) belong(s) to the group of " " protein-bound uremic toxin(s) with molecular weight(s) <8 kDa. Further studies and fractionation techniques are however needed to decipher the exact molecular nature of the stimulating compound(s). Plasma for haemodialysis patients elicited similar increase in ZAG content in adipose cells suggesting that the stimulating factor was not removed by the haemodialysis process. In contrast, plasma from
peritoneal dialysis patients did not elicit any change in ZAG content ( Figure 1B ). This observation desserves some comments. Because of their strong protein binding, protein-bound toxins are poorly removed by classical hemodialysis strategies, even using large pore dialysis membranes (32). In contrast with hemodialysis (an intermittent dialysis strategy), peritoneal dialysis is characterized by slow but continuous removal of solutes. Peritoneal dialysis is also associated with a peritoneal loss of albumin and an improved preservation of residual renal function. While clearance of protein-bound solutes was greater in hemodialysis patients than in those on peritoneal dialysis, paradoxically the plasma concentration of these protein-bound solutes was lower in patients on peritoneal dialysis than in those on hemodialysis (33,34). As an example, Pham et al (34) reported that the total concentration of p-cresyl sulfate, the prototype member of protein-bound uremic toxins, was lower in anuric patients on peritoneal dialysis than in those on hemodialysis. The discrepancy between the higher blood concentration and higher clearance of protein-bound solutes in patients on peritoneal dialysis compared with patients on hemodialysis is currently unexplained, but differences in intestinal generation or metabolism of these solutes could be involved (35). These observations support the fact that the stimulating factor(s) could be a protein-bound coumpound(s). We cannot however exclude that physiologic and/or metabolic differences in these patients should underlie the absence of effect of PD plasma on 3T3-L1 cells. This issue will however deserve further researches. We demonstrate for the first time that ZAG protein content was strikingly increased in white adipose tissue from Nx5/6 rodents or stage 5 CKD patients. We failed to find a significant correlation between adipose tissue ZAG protein level and plasma concentration of ZAG in CKD Stage 5 patients (r 0.03, p 0.843). In good agreement, the measurement of arterio-venous differences in human showed 2 = = that there was no significant contribution of WAT to the circulating levels of ZAG (36). In this study, in obese subjects, ZAG secretion from WAT increased significantly whereas serum levels remained unaltered. ZAG is therefore released from human WAT, but this tissue does not contribute significantly to the circulating levels. ZAG could therefore be regarded as a local factor in adipose tissue exerting its (44), ZAG could be a major lipid mobilizing factor and may contribute to the main CKD-associated metabolic disturbances.
In conclusion, as summarized in Figure 5 , we demonstrate for the first time that ZAG protein content is increased in white adipose tissue from CKD patients or CKD animal models. Our data suggest that uremic sera contain a protein-bound small MW factor (or factors) that stimulate(s) ZAG production by adipocytes. While our results are relevant to understand the metabolic disturbance in CKD patients, we did not identify the exact molecule in uremic plasma that mediates ZAG overproduction in adipose tissue. Our results demonstrate the importance of ZAG overproduction in CKD, through increased lipolysis and decreased lipogenesis, which could be a major contributor to dysmetabolism associated with CKD.
Methods
Human subjects
Twelve healthy adult volunteers, eight non dialyzed CKD patients (renal disease: 3 nephroangiosclerosis, 2 diabetes mellitus type 2, 1 polycystic disease, 1 glomerular sclerosis and 1 uropathy), five patients maintained on haemodialysis for a minimum of one year, and 4 peritoneal dialysis patients matched for age, gender and body mass index (BMI) were recruited at the University hospital in Lyon, France.
Haemodialysis (hemodiafiltration) therapy was performed three times weekly during four hours. Mean dialysis time was 12.38 0.75 ± hour/week and hemodialysis patients exhibited an equilibrated Kt/V of 2.07 0.23. Peritoneal dialysis patients exhibited a total Kt/V of ± 2.20 0.07 per week (see Supplementary Table 4 for clearance results). After an overnight fast, blood samples were obtained by ± venipuncture, except for dialysis blood samples that were obtained immediately before and after dialysis from mechanical bloodstream.
Blood samples were centrifuged at 3500 for 10 min to isolate plasma supernatant which were snap frozen in liquid nitrogen and stored × g at 20 C until use. Creatinine clearance was calculated using the Modification of the Diet in Renal Disease formula (MDRD). In a second −°e xperiment, seven CKD patients stage 5 and nine non CKD patients were recruited from an ongoing study to perform subcutaneous adipose tissue biopsies. Biopsies (2 3 g) were performed during elective surgery (peritoneal dialysis catheter for CKD patients and radical Animals were randomly divided into two groups: sham-operated (SO) and nephrectomized (Nx5/6). Animal experiments were performed under the authorization n 69-266-0501 (CarMeN lab, Direction D partementale des Services V t rinaires du Rh ne), All experiments°é é é ô were carried out according to the guidelines laid down by the French Minist re de l Agriculture (n 87-848) and the E.U. Council Directive
or the Care and Use of Laboratory Animals of November 24th, 1986 (86/609/EEC). After anaesthesia with sodium pentobarbital (35 mg/kg ip) and chlorpromazine (5 mg/kg ip), rats underwent surgical 5/6 renal mass reduction in two stages or sham operation. Animals were given morphine chlorhydrate (6 mg/kg ip) three times a day for 2 days to manage post-operative pain. Since uraemia could result in significant changes in food intake, SO rats were pair fed with Nx5/6 animals to prevent difference in feeding behaviour and eliminate animal weight as a variable in this study. Ten weeks after surgery, rats were deeply anesthetized with sodium pentobarbital (60 mg/kg ip).
Blood was withdrawn on heparinized syringe from puncture of the vena caeva. Blood samples were centrifuged at 3500 for 10 min to × g isolate plasma supernatant which were snap frozen in liquid nitrogen. Epididymal (eWAT), retroperitoneal (rWAT) and subcutaneous inguinal (scWAT) white adipose tissue were dissected out according to anatomical landmarks, weighted and snap frozen in liquid nitrogen for ZAG immunodetection. The muscle and hepatic lipids were extracted using Chloroform-Methanol (2:1, v/v) and total lipid content was estimated gravimetrically.
Cell culture
Mouse 3T3-L1 fibroblasts were obtained from the American Type Culture Collection (CL-173; ATCC, LGC Standard SARL, Molsheim, France). Cells were grown in 12-well plates in Dulbecco s modified Eagle s medium (DMEM) containing 25 mM D-glucose, 4
' ' mM glutamine, 25 mM Hepes buffer (GlutaMAX, Invitrogen, Illkirch, France) and supplemented with 100 IU/ml penicillin, 100 g/ml μ streptomycin, and 10 (v/v) heat inactivated (30 min, 56 C) foetal calf serum (Sigma Aldrich). Cultures were maintained at 37 C in a %°°w ater-saturated atmosphere containing 5 (v/v) CO . Adipocytes were studied 10 12 days after differentiation, which was induced by 
Lipolysis measurement
Lipolysis was measured, in baseline and stimulated (isoproterenol 10 M) conditions as the rate of glycerol release over a 1-h period.
μ Media were collected from the cells and glycerol in culture supernatants was measured by a colorimetric method using glycerol assay kits (R-biopharm, Saint-Didier, France).
Lipogenesis measurement
3T3-L1 adipocytes grown in six-well dishes were incubated for 16h with plasma pools as described above. Lipogenesis was then measured as the incorporation of C -acetate into total neutral lipids. 3T3-L1 cells were incubated in DMEM medium containing 1 by protein concentration estimated using Bradford assay.
Statistics
All data were analysed using GraphPad Prism v5.0 software (Graphpad software, La Jolla, USA) and were expressed as means ± SEM. Results were compared by one-way analysis of variance (ANOVA) followed when appropriate by post-hoc Tukey test. Simple comparisons were performed using Student s t-test. When appropriate, Welch s correction for inhomogeneity of variances was applied.
' '
Differences were considered significant at the P<0.05 level. for n 4 5 independent experiments in each group. Different letters indicate a significant difference at the p<0.05 level.
= -
Figure 3
ZAG content is increased in white adipose tissue from 5/6 nephrectomized rat and associated with fat mass loss and ectopic lipid redistribution Quantification of ZAG protein amounts was performed by Western Blotting in epididymal white adipose tissues of sham-operated (SO) (A) and nephrectomized (Nx5/6) rats. Quantifications of ZAG in WAT was performed by western blotting normalized to tubulin and expressed in arbitrary units (AU). Data are means SEM for n 6 7 in each group.
ZAG protein contents in WAT is correlated with proteinuria but ZAG content is increased in white adipose tissue from 5/6 nephrectomized mice fed a standard or a high fat diet White adipose tissue accretion in SO and Nx5/6 mice fed a low or high fat diet to increase fat deposition. Quantification of ZAG (A) (B) protein amounts was performed by Western Blotting in epididymal white adipose tissues of sham-operated (SO) and nephrectomized (Nx5/6) mice. Quantifications of ZAG in WAT was performed by western blotting, normalized to tubulin and expressed in arbitrary units (AU). Data are means SEM for n 6 7 in each group. ± = -
Figure 5
Schematic representation of ZAG contribution to dysmetabolism associated with chronic kidney disease. Abbreviation: BMI, body mass index, CKD, chronic kidney disease, CRP, C-reactive protein, scWAT, subcutaneous white adipose tissue. £ ZAG tissue content was analyzed by western blotting as described in methods and normalized to Tubulin content. Typical blots for non-CKD and CKD patients are shown in Supplementary Figure 4 .
